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ABSTRACT
Background. There is mixed evidence regarding the nature of
cognitive function in patients who have undergone renal trans-
plantation. The aim of this meta-analysis was to examine which
cognitive domains are impacted following kidney transplanta-
tion and how performance compares with non-transplanted
patients or healthy controls/normative data.
Method. A systematic search was conducted using keywords
within three databases (Embase, MEDLINE and PsychINFO),
yielding 458 unique studies, 10 of which met the inclusion criteria.
Neuropsychological tests were grouped into nine cognitive
domains and three separate analyses were undertaken within each
domain: (i) within subjects pre- versus post-transplant, (ii) trans-
planted versus non-transplanted patients and (iii) transplanted
versus healthymatched controls and standardized normative data.
Results. Transplanted patients showed moderate to large
improvements in the domains of general cognitive status
(g¼ 0.526), information and motor speed (g¼ 0.558), spatial
reasoning (g¼ 0.376), verbal memory (g¼ 0.759) and visual
memory (g¼ 0.690) when compared with their pre-operative
scores. Test scores in the same ﬁve domains were signiﬁcantly
better in post-transplanted patients when compared with
dialysis-dependant or conservatively managed chronic kidney
disease patients. However, post-transplanted patients’ perform-
ance was signiﬁcantly low compared with that of healthy con-
trols (and standardized normative data) in the domains of
executive functioning (g¼0.283), verbal ﬂuency (g¼0.657)
and language (g¼0.573).
Conclusions. Two key issues arise from this review. First,
domain-speciﬁc cognitive improvement occurs in patients after
successful transplantation. Nevertheless, transplanted patients
still performed signiﬁcantly below healthy controls in some
domains. Second, there are important shortcomings in existing
studies; the length of follow-up is typically short and only lim-
ited neuropsychological test batteries are employed. These fac-
tors are important in order to support the recovery of cognitive
function among patients following renal transplant.
Keywords: chronic kidney disease, cognition, dialysis, kidney
transplant, systematic review
INTRODUCTION
Chronic kidney disease (CKD) can result from multiple factors,
including hypertension, diabetes and genetic disorders [1–3].
End-stage kidney disease (ESKD) is the fifth and most severe
category of CKD and is defined as the inability of the kidneys to
metabolize and remove waste substances such as creatinine [4].
Patients suffering from ESKD depend on renal replacement
therapy (RRT) for survival. RRT options include kidney trans-
plantation, peritoneal dialysis (PD) and haemodialysis (HD) [5]
and transplantation is currently the recommended gold stand-
ard [6]. The majority of transplanted patients spend a period of
VC The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
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months or years dependent on dialysis before being trans-
planted, although a minority (22%) receive a transplant pre-
emptively, bypassing the need for maintenance dialysis [7].
CKD is a debilitating illness with a broad impact on physical
health and psychological function (both well-being and cognitive
function) [8, 9]. CKD has been shown to be an independent risk
factor for cognitive decline across multiple domains of function-
ing, including memory and spatial reasoning [10]. The onset
and course of cognitive difficulties is poorly understood, but
there is evidence that cognitive function may improve following
kidney transplantation [11]. There are various potential mecha-
nisms to account for the cognitive change experienced by CKD
patients. For instance, the impact of CKD on cerebral vascula-
ture may affect cognition [12]. Previous research has shown that
reduced creatinine clearance (between 15 and 60mL/min) is
associated with a 43% increase in stroke and white matter deteri-
oration, which are factors associated with dementia and cogni-
tive impairments [13]. In addition, CKD patients often have
elevated homocysteine levels [14], which in turn have been asso-
ciated with subclinical cerebral infarcts [15], high carotid
intima-media thickness [16] and cerebral white matter changes
[17], as revealed by magnetic resonance imaging studies employ-
ing diffusion -weighted sequences. While these are subclinical
associations, they can prompt cognitive impairment through
multiple mechanisms such as cerebral systemic inflammation,
oedema and atherosclerosis [18]. Although there are only lim-
ited data, another putative mechanism for cognitive decline in
this group relates to a possible increased risk of vascular demen-
tia in patients with CKD [19]. Vascular mechanisms may also
underlie cognitive changes noted in patients receiving dialysis
[20]. This may be caused by hypotension (a common result of
rapid reduction of blood volume during HD), cerebral oedema
due to excess water in the brain because of water retention or
even cortical atrophy as a result of dialysis [21]. Anaemia could
also contribute to cognitive difficulties experienced by those with
CKD. The prevalence of anaemia has been found to be twice as
high among CKD patients (15.4%) compared with the general
population (7.6%) [22]. Furthermore, the prevalence of anaemia
has been shown to increase with the severity of CKD, from 8.4%
at Stage 1 to 53.4% at Stage 5 [22]. Unlike other mechanisms,
which reflect permanent alterations of neural function, reversal
of anaemia is associated with a concomitant improvement in
cognitive function [23]. Thus there are several potential mecha-
nisms that contribute to poor cognitive status in CKD patients,
and the question remains open as to whether these impairments
recover with effective treatment of CKD.
Some studies suggest that cognitive decline of CKD can to
some extent be reversed following kidney transplantation [11,
24–26], while others indicate that cognitive decline may be exa-
cerbated by the adverse effects of immunosuppressive medica-
tions that patients are required to take after transplantation [27–
30] or due to mood disturbances. Cognitive impairments may
impact on post-transplant daily living. For instance, decreased
cognitive functioning (e.g. in memory and executive function
[31]) may lead to lapses in the self-administration of and adher-
ence to complex immunosuppressive medication regimes [32].
There is mixed evidence regarding the nature of cognitive
changes following kidney transplantation. Identification of the
precise nature of cognitive change is imperative for pre-transplant
advice and post-transplant clinical support. The aim of this meta-
analysis was to examine which cognitive domains are impacted fol-
lowing kidney transplantation and how performance compares
with non-transplanted patients or healthy controls/normative data.
MATERIALS AND METHODS
The review complies with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines
[33] (Supplementary data, Table S1).
Review strategy
Three databases were searched through the Ovid platform:
Embase (1947–February 2016), MEDLINE (1946–February
2016) and PsychINFO (1806–February 2016). No limits were
applied for publication dates. Search terms were categorized
into three blocks: Block 1, renal or kidney; Block 2, immuno-
suppression or transplant and Block 3, cognitive function* or
cogniti* or neuropsycho* or neuroimag* or memory or lan-
guage or attention or executive or spatial. A search was then
performed using the AND function combining the results of
the three blocks. Duplicates were omitted. Reference lists were
hand searched (backwards search) and a forward (citation)
search was conducted to identify additional relevant publica-
tions.Where relevant, authors were contacted to request further
information about the methodology or data.
Studies were conducted if they (i) reported cognitive
performance data for kidney transplant patients; (ii) included
relevant comparison data of either pre- or post-transplant
data, dialysis patients, CKD patients, healthy controls or
standardized norms; (iii) were written in English and (iv) age
>18 years. Exclusion criteria included reviews of conference
abstracts, case studies, dissertations or book chapters. The fol-
lowing information was systematically extracted from each
identified article and entered into a pre-designed data acquisi-
tion sheet: authors (year of publication), aims, design, country
of origin, sample size (age range), comparison groups, treat-
ment type, stage of CKD, prospective follow-up period, length
of immunosuppressive treatment, time tested after transplant
surgery, cognitive domains tested and findings.
Methodological quality assessment
Selected articles underwent quality assessment using an
11-item quality assessment tool [34]. Two researchers under-
took this process independently and issues were resolved
through consensus. Scoring was dependant on the extent to
which a study fulfilled each criterion: a score of two was
assigned if a study fully met the criterion, one was assigned if it
partially met the criterion and zero was assigned if a criterion
was not met. Criteria were excluded if they were not applicable
to a particular study. An average score was calculated and stud-
ies were categorized as high quality (score > 1.50), medium
(score 1.00–1.50) or low quality (score< 1.00).
Meta-analysis procedure
Outcome measures were grouped into nine cognitive
domains (Supplementary data, Table S2): attention, executive
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function, general cognitive status, information and motor
speed, spatial reasoning, language, verbal fluency, verbal memo-
ry and visual memory. Three separate meta-analyses were
performed: (i) within subjects pre- versus post-transplant,
(ii) transplanted versus non-transplanted patients and (iii)
transplanted versus healthy matched controls and standardized
normative data. Data from each study could be included in one,
two or all three analyses depending on study design. Random
effects models were used to calculate the effect sizes (Hedges’ g)
for changes in cognitive performance in each of the nine
domains. The Hedges’ g effect size is a measure of the difference
between groups reported on a common dimensionless scale. It
is obtained by dividing the difference of each measure by the
pooled and weighted standard deviation of the sample. An
effect size (g) of 0.2 is regarded as being small, because 85% of
the area from normally distributed values shared between two
groups of equal size and variability overlap; 0.5 is regarded as
medium, because 66% of normally distributed values overlap;
and 0.8 is regarded as large, because only 20% of combined nor-
mally distributed values overlap [35].
Heterogeneity between articles was assessed using I2, s2 and
Q tests. The I2 statistic is especially relevant to this review, since
it allows researchers to approximate the proportion of total var-
iation in the effect sizes across studies. Higher I2 values indicate
higher levels of heterogeneity. These proportions have been
categorized into low, moderate and high (25%, 50% and 75%,
respectively) I2 values representing various levels of heterogene-
ity [36]. Publication bias was assessed using funnel plots with
the trim and fill method (Figure 2). Meta-analysis calculations
were undertaken with Comprehensive Meta-Analysis software
(version 2; Biostat, Englewood, NJ, USA) [37].
RESULTS
The search methodology identified 472 articles, which was
reduced to 458 by eliminating duplicates (Figure 1). After screen-
ing titles and abstracts, 442 non-relevant articles were excluded.
The remaining 16 articles were retrieved in full text for review
against the inclusion and exclusion criteria. Three articles were
excluded as they were not relevant to the review [38–40] and a
further two studies were excluded because they reported no post-
transplant comparative date [41, 42]. A backwards search identi-
fied one article and a forwards search revealed two further
articles. Of these 14 articles, 3 were excluded because they were
FIGURE 1: Overview of search methodology: (i) Koushik et al. [38], Olbrisch et al. [39] and Wolkowitz et al. [40]; (ii) Hailpern et al. [41] and
Kurella et al. [42]; (iii) Carrasco et al. [43] and Gutierrez-Dalmau and Campistol [44] and (v) Harciarek et al. [45].
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systematic reviews or a dissertation without empirical findings.
In addition, one article had a 40% participant overlap with a pre-
vious study by the same authors and therefore the earlier article
was excluded [45, 46]. Ten articles remained; six studies were
categorized as high quality [11, 24, 26, 30, 46, 47] and four as
moderate quality [14, 25, 48, 49]. Four studies used a longitudinal
design in which follow-up assessment periods ranged from 6 to
28months post-transplant.
The most frequently assessed domain across all studies was
verbal memory (Supplementary data, Table S3), which was
FIGURE 2: Funnel plots assessing publication bias by analyses conducted, cognitive domain effect sizes and signiﬁcance level. Hollow symbols
represent publication bias of studies included and solid symbols represent imputed studies required to avoid publication bias.
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assessed across seven studies. Performance scores from one
assessment in an included study were omitted because distinct
scores were not provided for the forward and backward parts of
the digit span test [47]. Study sample sizes ranged from 15 to
262 (Table 1), with a total sample size of 1118. The age range
across the studies was 42–59 years. Publication bias was
assessed by visually inspecting funnel plots for asymmetry
(Figure 2). Some bias was present, but when plots were re-
analysed with the trim and fill method, no significant changes
in effect size were found.
Cognitive findings by domain
All nine cognitive domains (Supplementary data, Table S2)
were entered into the analyses.
Within subjects pre- versus post-transplant
Three studies in this analysis included pre-transplant
patients on HD [14, 24, 46] and one study included pre-trans-
plant patients on HD or PD [26].
Post-transplantation performance showed significant
improvement in general cognitive status {g¼ 0.526 [95% confi-
dence interval (CI) 0.138–0.915], P¼ 0.008, I2 ¼ 0.000}, infor-
mation and motor speed [g¼ 0.558 (95% CI 0.059–1.057),
P¼ 0.029, I2 ¼ 49.693], spatial reasoning [g¼ 0.376 (95% CI
0.033–0.719), P¼ 0.053, I2 ¼ 0.000], verbal memory [g¼ 0.759
(95% CI 0.411–1.202), P¼ 0.002, I2 ¼ 22.201] and visual
memory [g¼ 0.690 (95% CI 0.291–1.089), P< 0.001, I2¼ 0.000]
(Figure 3). No significant effect sizes were observed for the other
domains.
Transplanted versus non-transplanted patients
Kidney transplant patients’ scores were compared with non-
transplanted dialysis-dependant patients in four studies, one of
which measured cognition in patients who were on HD [47],
while the remaining three assessed patients who were dialysing
through HD or PD [25, 46, 49]. One study was also included in
this analysis that compared kidney transplant patients with
individuals with CKD [estimated glomerular filtration rate
(eGFR)<60mL/min/1.73 m2] who had not received a trans-
plant or dialysis [48]. Scores of patients measured after they had
been transplanted and compared with patients who are dialy-
sis-dependant or CKD managed showed significantly better
general cognitive status performance [g¼ 0.425 (95% CI 0.203–
0.648), P< 0.001, I2 ¼ 0.000], information and motor speed
[g¼ 0.457 (95% CI 0.054–0.860), P¼ 0.026, I2 ¼ 71.942], spa-
tial reasoning [g¼ 0.596 (95% CI 0.011–1.203), P¼ 0.054, I2
¼ 0.000], verbal memory [g¼ 0.477 (95% CI 0.010–0.944),
P¼ 0.046, I2 ¼ 76.927] and visual memory [g¼ 0.792 (95% CI
0.185–1.399), P¼ 0.011, I2 ¼ 0.000]. However, no significant
differences were found in domains of attention, executive func-
tioning, language and verbal fluency (Figure 3).
Transplanted versus healthy matched controls and
standardized norms
Transplanted patients’ scores were compared with healthy
matched control participants or standardized norms. One study
compared patients with healthy controls first while they were
dependent on HD and then after they had been transplanted
[46]. Another study made similar comparisons but did not re-
test healthy controls after HD patients were transplanted [14].
Five further studies were cross-sectional and assessed cognition
at one time point following transplantation and compared with
healthy controls or standardized norms [11, 30, 47, 48]. Healthy
controls were matched to transplanted patients according to
age, mean years of education, gender, baseline intelligence
(Mini Mental State Examination, vocabulary), physical activity,
occupation, marital status, comorbid conditions and biological
factors (haemoglobin, serum creatinine, blood urea nitrogen,
eGFR) across studies.
Significant differences were found in executive functioning
[g¼0.283 (95% CI0.535 to0.030), P¼ 0.030, I2¼ 0.000],
language [g¼0.573 (95% CI 1.095 to 0.051), P¼ 0.032,
I2¼ 0.000] and verbal fluency [g¼0.657 (95% CI 1.080 to
0.233), P< 0.01, I2 ¼ 0.000], in which post-operative trans-
plant patients scored below healthy matched controls and
standardized norms (Figure 3). No significant differences were
found in domains of attention, spatial reasoning, information
and motor speed, general cognitive status, verbal memory and
visual memory across studies (Figure 3).
DISCUSSION
The aim of this meta-analysis was to examine which cognitive
domains were impacted following kidney transplantation and
how performance compares with non-transplanted patients or
healthy controls/normative data. The meta-analysis identified
that cognitive performance is better in patients who have
received a transplant compared with those who are dialysis
dependant or CKD managed in the domains of verbal and vis-
ual memory, spatial reasoning, processing speed and general
cognitive status. While reviewing changes within people who
received a transplant, significant improvements were apparent
in the domains of general cognitive status, information and
motor speed, spatial reasoning, verbal memory and visual
memory. These changes appear to be stable, as cognitive
improvement remained measurable at the 1-year [46] and even
the 2-year follow-up [24]. However, these findings highlight
that transplant patients are unlikely to recover fully after trans-
plant surgery, as patients still performed significantly below
healthy matched controls/normative data in three cognitive
domains (executive function, verbal fluency and language).
Moreover, cognition in some domains (attention, executive
function, verbal fluency and language) did not improve after
transplantation (even with long-term follow-up) compared
with pre-transplant levels and was not superior compared with
dialysis patients.
Improved understanding of the aetiology of cognitive
impairment after kidney transplantation may enable develop-
ment of interventions to improve or maintain cognition [50,
51]. Determining whether there are effects upon cognition of
specific immunosuppressive medication has important clinical
implications. Impairments in attention and executive function-
ing in kidney transplant patients treated with either tacrolimus
or sirolimus have been reported [30]. In contrast, no such cog-
nitive side effects were reported among cyclosporine-treated
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Table 1. Summary of study key signiﬁcant ﬁndings and sample size information
Study/date Sample and age (years) Design Comparative group,
n (age6 SD)
Time tested post-
transplant
Outcomes: domains
assessed
Kramer et al. [14],
Austria
15 transplant patients
(456 13) previously
on HD
Prospective longitudinal
Within-subjects pre-
transplant dialysis
patients assessed after
transplantation compared
with healthy controls; 14
6 5-month follow-up
Same sample assessed
after transplant HD:
15 (456 13)
Healthy controls:
45 (456 13)
14months General cognitive status
Information and motor
speed
Harciarek et al. [46],
Poland
27 transplant patients
(46.16 10.9) previously
on HD: 17, PD: 10
Prospective longitudinal
Within-subjects pre-
transplant dialysis
patients assessed after
transplantation compared
with dialysis and healthy
controls; 8-month and
20-month follow-up
Subsample of transplant
patients assessed after
transplantation com-
pared with those still
on dialysis:
Still dialysing:
18 (44.9611.8)
HD: 12
PD: 6
Healthy controls:
30 (47.236 10.2)
None stated Attention
Executive function
General cognitive status
Information and motor
speed
Language
Spatial reasoning
Verbal ﬂuency
Verbal memory
Visual memory
Griva et al. [26],
United Kingdom
28 transplant patients
(follow-up age not stated)
previously on HD: 10,
PD: 18
Prospective longitudinal
Within-subjects pre-
transplant dialysis
patients assessed after
transplantation; 6-month
follow up
Same sample assessed
after transplant dialysis:
28 (44.046 12.01)
HD: 10
PD: 18
Standardized norms
6months Executive function
Information and
motor speed
Verbal memory Visual
memory
Radic et al. [24],
Croatia
21 transplant patients
(45.146 7.86)
previously on HD
Prospective longitudinal
Within-subjects pre-
transplant dialysis
patients assessed after
transplantation; 206 8-
month follow-up
Same sample assessed
after transplant
HD: 21 (45.146 7.86)
20.5months Executive function
Spatial reasoning
Verbal memory
Griva et al. [25],
United Kingdom
117 transplant patients
(50.266 12.33)
Cross-sectional transplant
patients compared with
dialysis patients
Dialysis:
145 (50.126 14.26)
HD: 77
PD: 68
None stated Executive function
Information and motor
speed
Verbal memory
Troen et al. [11], Israel 183 transplant patients
(546 9.5)
Cross-sectional transplant
patients assessed only
compared with norms
Standardized norms None stated Executive function
Information and motor
speed
Spatial reasoning
Verbal memory
Gelb et al. [48],
Canada
42 transplant patients
(55.246 10.96)
Cross-sectional transplant
patients compared with
healthy controls and CKD
patients
CKD patients:
45 (59.676 11.88)
Healthy controls:
49 (57.006 13.59)
None stated Executive function
Verbal memory
Martinez-Sanchis et al.
[30], Spain
32 transplant patients
(42.696 8.28)
Cross-sectional transplant
patients compared with
healthy controls
Healthy controls:
10 (37.206 9.90)
None stated Attention
Executive function
Information and motor
speed
Verbal ﬂuency
Verbal memory
Visual memory
Anwar et al. [47],
Egypt
50 transplant patients Cross-sectional transplant
patients compared with
dialysis and healthy
controls
Dialysis: 50 (456 9.5)
Healthy controls: 30
(456 9.5)
None stated Executive function
General cognitive status
Information and motor
speed
Ozcan et al. [49],
Turkey
69 transplant patients
(50.96 16.5)
Cross-sectional transplant
patients compared with
dialysis patients
Dialysis: 112 (51.216
13.45)
HD: 54 (51.16 12.5)
PD: 58 (51.336 14.4)
None stated General cognitive
status
Age6 SD refers to mean age6 standard deviation.
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patients, who performed similarly to healthy controls after
transplantation [30]. Unfortunately, any discrete cognitive out-
comes related to medication treatments in the study had to be
averaged across immunosuppressive groups to be included in
the review, losing the effects of individual immunosuppressive
therapies on cognition. However, it is well established that
immunosuppressive medication can impact neural function. In
normal central nervous system function, the cytokine interleu-
kin-2 (IL-2) has been demonstrated to be essential for neuro-
genesis and cognition [52]; its production and action is
inhibited by a number of immunosuppressive drugs, including
tacrolimus, cyclosporine and sirolimus [53–55]. In addition,
dopamine and acetylcholine have been found to be innervated
to the prefrontal and parietal regions [56], which may be
involved in executive function tasks requiring working mem-
ory, visuospatial working memory, planning and inhibition
[29]. Innervation of these neurotransmitters has been shown to
be mediated through IL-2 [57]. Thus interference from immu-
nosuppression in the midbrain area (substantia nigra), where
IL-2 is abundant, could lead to a blockade in neurotransmitter
processes essential for executive functions [58]. The severity of
immunosuppressive-induced cognitive changes appears to be
reversible and related to the length of immunosuppressive
exposure rather than to drug dosages [59–61]. Since tacrolimus
and sirolimus have been associated with cognitive impairment
in past research [30], it is important to assess the individual
FIGURE 3: Cognitive performance by domains of transplant patients’ baseline performance compared with follow-up. Transplant patients
compared with non-transplanted patients and transplant patients compared with matched healthy controls and standardized norms.
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effects of specific immunosuppressant medications on cogni-
tion. Moreover, this is due to the neural pathways in which
these drugs inhibit IL-2. Tacrolimus inhibits IL-2 through
calcineurin inhibition [62], whereas sirolimus inhibits T-cell
and B-cell activation through action on mammalian target of
rapamycin, which regulates cell growth, proliferation and
motility [63]. These underlying mechanisms could have pleio-
tropic effects influencing various phenotypic traits [64, 65]. The
possibility of medication-specific cognitive impairment should
be one of the issues discussed to fully prepare and inform
potential transplant recipients.
There are several alternative mechanisms that might
underlie sustained cognitive impairment in kidney trans-
plant patients. There is a well-established link between mood
disturbance and cognitive changes, particularly in the
domains of attention, executive function and working mem-
ory [66–68]. Prevalence rates of depression in kidney trans-
plant patients range between 13 and 46% [69–71]. While
some studies of depression in dialysed patients who subse-
quently received a transplant typically report lower levels of
depression after transplantation [26], others found no signif-
icant differences or interactions in depression levels between
dialysed patients pre- and post-transplantation [45, 46]. The
literature illustrates that depression is prevalent in transplant
patients. However, uncertainty exists about the carry-over
effects of depression from dialysis to transplantation due to
mixed findings.
Posterior reversible encephalopathy syndrome (PRES) is
an identified mechanism of cognitive impairment and may
affect brain function in kidney transplant patients in the
short term [72]. In most cases, irregularities are confined to
bilateral frontal lobes, right occipital cortices, and parietal
regions [73], which are regions important to executive func-
tions [74, 75]. However, longitudinal follow-up studies
included in this review suggest that symptoms of PRES are
resolved in the long term compared with pre-transplant levels
[14, 24, 46]. Investigations of PRES have been explored, but
only on a case study [76] or small sample size basis [77].
Therefore, the role and identification of PRES warrants fur-
ther investigation in longitudinal designs. Other variables
including cerebrovascular disease, subclinical infarcts and
carotid intima-media thickness could merge with more acute
risk factors to influence cognitive changes after transplanta-
tion [16, 17]. Delineating between these chronic and acute
risk factors should be explored through further research for
effective management. Also possible is that improved toxin
clearance following transplantation results in improved cog-
nitive performance [46]. Poorer toxin clearance (indicated by
a lower eGFR) has been shown to correlate with poorer per-
formance on tests of memory and executive function [11].
Studies that assess the trajectory of cognitive function and
how that correlates with toxin clearance would help test this
hypothesis.
There are several limitations in the meta-analysis presented
here. Only four studies assessed cognition longitudinally
(6months to 2 years follow-up periods). Moreover, it should be
noted that only English-language studies were included and
that non-English-language studies may influence the overall
findings reported here. Additionally, discrepancies exist
between global approaches to the management of renal trans-
plant patients and practices change over time. Therefore, the
meta-analysis and review conducted should be interpreted with
caution, as location and time are relevant to outcomes. Another
concern is that studies lack large enough sample sizes required
to match for multiple comparisons across dialysis, transplant
and healthy patients. Therefore, study designs lacked the power
to compare for multiple confounds across samples and findings
may be biased. Publication bias was apparent in the within-
subjects comparisons and non-transplant versus transplant
patient comparisons. However, when the trim and fill method
was used to adjust for the suspected bias, only marginal effect
size shifts were apparent, indicating no significant changes even
with imputed studies. In addition, studies employed study-
specific neuropsychological measures to assess cognition, which
makes it challenging to compare and group tests into domains
because sensitivities and specificities of tests may differ accord-
ing to the population being studied [78]. Furthermore, cut-off
scores defined as being abnormal or normal may vary for each
incorporated test [78].
Organization of assessments was grouped into cognitive
domains with specific distinctions made between certain cogni-
tive domains. Categorization of tests primarily dependent on
language and executive control abilities were classified as verbal
fluency. However, those tasks involving predominantly execu-
tive functions such as inhibition and categorization [79] with a
working memory retrieval component were grouped in the
executive function domain. Arguably, the validity of both verbal
fluency and executive function assessments have been found to
overlap [80]. Due to the hybrid nature of both the domains, the
number of possible variations that tests could be classified as
could vary overall outcomes. The development of a cognitive
taxonomy for the classification of assessments is required and
recommended to limit this shortcoming.
The analysis included a pre- versus post- within-subjects
design. One weakness of the studies in this analysis (pre- versus
post-) is that a control group was not used to control for
changes in cognition of patients over time [81]. Therefore, a
control group of ESRD patients actively waiting for a transplant
from the deceased donor list is recommended in further
research. This group represents the closest match to transplant
patients postoperatively and may assist in controlling for con-
founding factors among both groups over time.
We know of no interventions that have been developed spe-
cifically to mitigate the effects of cognitive changes among
transplant patients. However, cognitive interventions have been
shown to be effective in improving cognitive functioning in
other groups, including executive functioning after brain injury
and mild cognitive impairment in other clinical populations,
and it would be useful to test their benefit for kidney transplant
recipients [82, 83]. Our findings provide evidence for restora-
tion of cognitive function in transplanted patients to pre-end-
stage but not normal levels in the majority of cognitive
domains. There is a need for research that identifies the basis
for this improvement. The recovery of cognitive abilities may
not extend to the important domain of executive functions and
may be inhibited by some groups of immunosuppressive
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medication. Thus, there is a strong case for additional research
aimed at supporting optimal cognitive outcomes among
patients receiving kidney transplants.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
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